Navigation Links
CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
Date:12/13/2012

KING OF PRUSSIA, Pa., Dec. 13, 2012 /PRNewswire/ -- CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com. This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose. 

"PI is a genetic disorder that can have a dramatic impact on a person's ability to participate in daily activities due to a weakened immune system that leaves him or her vulnerable to common infections. If PI is left untreated, infections can occur – some severe enough to cause permanent and irreversible organ damage," said Dr. John Sleasman, Chief of the Division of Pediatric Allergy, Immunology and Rheumatology at the University of South Florida. "While the condition is not curable, immunoglobulin treatments can help supplement the immune system to allow patients to lead active lives."

Carl is just one of approximately 250,000 individuals (or one in 1,200) diagnosed with PI in the United States. Race fans watching Carl perform high flying jumps and difficult maneuvers would never know that he requires a weekly subcutaneous infusion (i.e., under the skin) of immunoglobulin to manage his condition, which helps him stay healthy to compete at the professional level.

"Growing up I didn't know anyone else affected by primary immunodeficiency," said Carl, who was diagnosed with PI at a year old. "For this reason, I am encouraging everyone affected by PI to visit www.IamaChamPIon.com and post their 'ChamPIon' story. Collectively, we can support and inspire each other to pursue our dreams." 

In addition to providing an outlet for people with PI to share their stories, the I Am a ChamPIon website offers information about the condition and identifying the warning signs for diagnosis. At www.IamaChamPIon.com you can also watch a video of Carl on the race track and discussing his journey to becoming a professional Supercross racer despite PI.  

About Primary Immunodeficiencies   
Nearly 150 types of PIs exist. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, may even result in death.

Collectively, PIs affect an estimated 10 million people worldwide. Due to the X-linked inheritance in many PI syndromes, more males are affected than females.  For more information on PI, please visit www.IamaChamPIon.com or contact the leading PI patient advocate groups in the U.S., the Immune Deficiency Foundation and the Jeffrey Modell Foundation.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited  (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Media Contacts:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com

Etanjalie Ayala
Weber Shandwick
212-445-8225
eayala@webershandwick.com

Judy Welage
Weber Shandwick
212-445-8308
jwelage@webershandwick.com


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
4. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
5. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
6. Veterinary Bioscience Institute (VBI) and a-tune software, Inc. Partnership
7. Chimerix To Present At Therapeutic Area Partnerships Meeting
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. Bluechiip Signs Strategic Partnership with Gentris Corporation
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):